![]() |
Name |
2-chlor-4′-hydroxy-6-methoxycarbonyl-2′-methyl-3,5,6′-trimethoxy-diphenyl ether
|
Molecular Formula | C18H19ClO7 | |
IUPAC Name* |
methyl3-chloro-2-(4-hydroxy-2-methoxy-6-methylphenoxy)-4,6-dimethoxybenzoate
|
|
SMILES |
COC(=O)c1c(OC)cc(OC)c(Cl)c1Oc1c(C)cc(O)cc1OC
|
|
InChI |
InChI=1S/C18H19ClO7/c1-9-6-10(20)7-13(24-4)16(9)26-17-14(18(21)25-5)11(22-2)8-12(23-3)15(17)19/h6-8,20H,1-5H3
|
|
InChIKey |
JUYOFEUYUZLVST-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 382.8 | ALogp: | 4.0 |
HBD: | 1 | HBA: | 7 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.5 | Aromatic Rings: | 2 |
Heavy Atoms: | 26 | QED Weighted: | 0.731 |
Caco-2 Permeability: | -4.784 | MDCK Permeability: | 0.00002340 |
Pgp-inhibitor: | 0.009 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.015 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.018 |
Blood-Brain-Barrier Penetration (BBB): | 0.027 | Plasma Protein Binding (PPB): | 96.21% |
Volume Distribution (VD): | 0.626 | Fu: | 7.32% |
CYP1A2-inhibitor: | 0.75 | CYP1A2-substrate: | 0.968 |
CYP2C19-inhibitor: | 0.926 | CYP2C19-substrate: | 0.819 |
CYP2C9-inhibitor: | 0.796 | CYP2C9-substrate: | 0.923 |
CYP2D6-inhibitor: | 0.231 | CYP2D6-substrate: | 0.909 |
CYP3A4-inhibitor: | 0.781 | CYP3A4-substrate: | 0.673 |
Clearance (CL): | 9.707 | Half-life (T1/2): | 0.677 |
hERG Blockers: | 0.015 | Human Hepatotoxicity (H-HT): | 0.066 |
Drug-inuced Liver Injury (DILI): | 0.264 | AMES Toxicity: | 0.029 |
Rat Oral Acute Toxicity: | 0.911 | Maximum Recommended Daily Dose: | 0.816 |
Skin Sensitization: | 0.782 | Carcinogencity: | 0.027 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.591 |
Respiratory Toxicity: | 0.765 |